Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
David B. Page, Harry D. Bear, Sangeetha Prabhakaran, et al.
npj Breast Cancer (2019) Vol. 5, Iss. 1
Open Access | Times Cited: 74

Showing 1-25 of 74 citing articles:

LncRNA GATA3‐AS1 facilitates tumour progression and immune escape in triple‐negative breast cancer through destabilization of GATA3 but stabilization of PD‐L1
Ming Zhang, Ning Wang, Peng Song, et al.
Cell Proliferation (2020) Vol. 53, Iss. 9
Open Access | Times Cited: 139
The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment
Maximilian Haist, Henner Stege, Stephan Grabbe, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 210-210
Open Access | Times Cited: 138
Role of Immunotherapy in Breast Cancer
Saya Jacob, Laura A. Huppert, Hope S. Rugo
JCO Oncology Practice (2023) Vol. 19, Iss. 4, pp. 167-179
Open Access | Times Cited: 51
Abscopal effect in radioimmunotherapy
Milad Ashrafizadeh, Bagher Farhood, Ahmed Eleojo Musa, et al.
International Immunopharmacology (2020) Vol. 85, pp. 106663-106663
Closed Access | Times Cited: 112
Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity
Marka R. Crittenden, Lauren Zebertavage, Gwen Kramer, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 98
Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance
Rosalynd Upton, Allison Banuelos, Dongdong Feng, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 29
Open Access | Times Cited: 97
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
Leisha A. Emens, Sylvia Adams, Ashley Cimino‐Mathews, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 8, pp. e002597-e002597
Open Access | Times Cited: 68
Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape
Kristin C. Hicks, Paul L. Chariou, Yohei Ozawa, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 60
Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer
Katherine Sanchez, Isaac Kim, Brie Chun, et al.
Breast Cancer Research (2021) Vol. 23, Iss. 1
Open Access | Times Cited: 58
Extracellular vesicle–based drug delivery in cancer immunotherapy
Sajad Najafi, Jamal Majidpoor, Keywan Mortezaee
Drug Delivery and Translational Research (2023) Vol. 13, Iss. 11, pp. 2790-2806
Open Access | Times Cited: 38
CAR T-cell therapy for triple-negative breast cancer: Where we are
Yuetao Xie, Yi Hu, Nawu Zhou, et al.
Cancer Letters (2020) Vol. 491, pp. 121-131
Closed Access | Times Cited: 63
Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
Simona Camorani, Margherita Passariello, Lisa Agnello, et al.
Journal of Experimental & Clinical Cancer Research (2020) Vol. 39, Iss. 1
Open Access | Times Cited: 51
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression
Benedetta Pellegrino, Zuzana Hlavata, Cristina Migali, et al.
Molecular Diagnosis & Therapy (2021) Vol. 25, Iss. 4, pp. 409-424
Open Access | Times Cited: 49
Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer
Jodi M. Carter, Mei‐Yin C. Polley, Roberto A. Leon‐Ferre, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 20, pp. 5628-5637
Open Access | Times Cited: 48
Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer
Siddhartha Das Pramanik, Amit Kumar Halder, Ushmita Mukherjee, et al.
Frontiers in Chemistry (2022) Vol. 10
Open Access | Times Cited: 31
High expression COL10A1 promotes breast cancer progression and predicts poor prognosis
Weijian Zhou, Yuting Li, Dingyi Gu, et al.
Heliyon (2022) Vol. 8, Iss. 10, pp. e11083-e11083
Open Access | Times Cited: 29
Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer
Sasagu Kurozumi, Kyoichi Kaira, Hiroshi Matsumoto, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 28
Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the Dana‐Farber Cancer Institute, 2011 to 2019
Yuanming Xu, Natalie Wen, Stephen T. Sonis, et al.
Cancer (2021) Vol. 127, Iss. 11, pp. 1796-1804
Open Access | Times Cited: 38
The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy
Patience Setordzi, Xing Chang, Zi Liu, et al.
European Journal of Pharmacology (2021) Vol. 895, pp. 173867-173867
Closed Access | Times Cited: 34
The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors
Sajad Najafi, Jamal Majidpoor, Keywan Mortezaee
Life Sciences (2022) Vol. 310, pp. 121138-121138
Closed Access | Times Cited: 24
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics
Kamal S. Saini, Kevin Punie, Chris Twelves, et al.
Expert Opinion on Biological Therapy (2021) Vol. 21, Iss. 7, pp. 945-962
Open Access | Times Cited: 32
Imiquimod-gemcitabine nanoparticles harness immune cells to suppress breast cancer
Bijay Singh, Sushila Maharjan, Daniel C. Pan, et al.
Biomaterials (2021) Vol. 280, pp. 121302-121302
Closed Access | Times Cited: 32
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer
Idoko Salifu, Navneet Singh, Maria Berraondo, et al.
Cancer Treatment and Research Communications (2023) Vol. 36, pp. 100713-100713
Open Access | Times Cited: 12
Immunotherapies against HER2-Positive Breast Cancer
Santiago Duro‐Sánchez, Macarena Román Alonso, Joaquı́n Arribas
Cancers (2023) Vol. 15, Iss. 4, pp. 1069-1069
Open Access | Times Cited: 11
Immune Microenvironment in Breast Cancer Metastasis
Bin‐Zhi Qian, Ruoyu Ma
Advances in experimental medicine and biology (2025), pp. 413-432
Closed Access
Page 1 - Next Page

Scroll to top